The company is addressing a critical gap in fibromyalgia treatment: undiagnosed obstructive sleep apnea (OSA). With up to 90% of sleep-related breathing disorders going undiagnosed, Vivos is ...

Year over year product revenue increased 26%Operating expenses declined 21% and year over year operating loss decreased 35%Management to Host ...

To access Vivos’ investor conference call, please dial (800) 717-1738, or for international callers, (646) 307-1865. A replay will be available shortly after the call and can be accessed by dialing ...

The global sleep apnea devices market report consists of exclusive data on 39 vendors. The competitive landscape of sleep apnea devices is dynamic, w ...

Good day, everyone, and welcome to the Vivos Therapeutics Full Year 2024 Earnings Conference Call. [Operator Instructions] This conference call is being recorded, and a replay of today's call will be ...

LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the ...